AEHR TEST SYSTEMS (AEHR): what the price requires
At today's price, AEHR TEST SYSTEMS (AEHR) is priced for today's economics sustained for ~40.0 years+. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high.
Generated: 2026-07-19 · Source: https://boothcheck.com/report/AEHR
Headline
| Field | Value |
|---|---|
| Ticker | AEHR |
| Company | AEHR TEST SYSTEMS |
| Current price | $81.04/sh |
What The Price Requires (Inversion)
The assumption today's price embeds, recovered by inverting the valuation.
| Field | Value |
|---|---|
| Inversion basis | revenue-multiple |
| EV / sales paid | 51.0x |
| Steady-state operating margin assumed | 16.2% |
Beyond 25%/yr sustained for 40 years; not resolvable as a revenue bet. The inversion reports a bound, not a solved point.
The company earns no operating profit yet; the inversion runs on the revenue multiple and an assumed steady-state margin.
Solve inputs: computed at a 16.4% cost of capital; growth searched up to the 25% self-funding ceiling.
Reconcile: at the x-ray's 9.3% required return this reads ~23.5 years; the models below use their own rates.
How unusual the bet is: extreme
| Reference | Value |
|---|---|
| vs own history | +0.21σ |
| sustained it ~5 years at this level | 30% |
| implied end-window share | 0% |
Valuation X-Ray
Every valuation family lands below the price. The price therefore requires assumptions beyond what those standard frames encode.
How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.
| Family | Median price/FV | Models | Reads |
|---|---|---|---|
| Asset | 18.92x | 2 | expensive |
| Earnings | — | 0 | — |
| Relative | — | 0 | — |
| Growth | 16.61x | 1 | expensive |
Families that call it expensive: Asset, Growth
The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.2%); the inversion above states its own rate.
Per-Model Detail (n=3)
| Model | Family | FV | Price/FV | Applicable | Methodology |
|---|---|---|---|---|---|
| DCF Perpetual Growth | Growth | $0.00 | — | no | Negative/zero FCF — equity value floored at $0 |
| DCF Exit Multiple | Growth | $0.00 | — | no | Negative/zero FCF or EBITDA — equity value floored at $0 |
| Relative Valuation | Relative | $3.69 | 21.96x | yes | P/S fallback (negative EPS): Sector P/S 2.5x × TTM revenue — excluded from consensus (excluded from median) |
| Simple DDM | Growth | — | — | no | — |
| Two-Stage DDM | Growth | — | — | no | — |
| Simple Excess Return | Asset | $4.52 | 17.93x | yes | Book value floor: BV/sh $4.52, ROE negative |
| Two-Stage Excess Return | Asset | $4.07 | 19.91x | yes | Book value with convergence: BV/sh $4.52, ROE converges to ke |
| Discounted Future Market Cap | Growth | $4.88 | 16.61x | yes | Rev $0.0B, growth -15% (input: historical growth; tapered), Terminal P/S: 10.5x / 15.0x / 19.5x (bear / base = today's held flat / bull, cap 15x) |
| Peter Lynch Fair Value | Relative | $0.00 | — | no | Negative/zero EPS — earnings-based value floored at $0 |
| Margin Trajectory | Growth | — | — | no | — |
| Earnings Power Value | Earnings | $0.71 | 114.13x | yes | Normalized EBIT (5y avg op income, one-time charges added back) $0.00B × (1−21%) / WACC 9.2% → EPV (no growth) (excluded from median) |
| Residual Income | Asset | — | — | no | — |
| Graham Number | Asset | — | — | no | — |
| EV/EBITDA Relative | Relative | — | — | no | — |
| FCF Yield | Earnings | — | — | no | — |
| SBC-Adj FCF Yield | Earnings | — | — | no | — |
| Ben Graham Formula | Earnings | — | — | no | — |
| ROIC-Justified P/B | Asset | — | — | no | — |
| P/Sales Sector | Relative | $3.69 | 21.96x | yes | Revenue $0.05B × sector P/S 2.5x (excluded from median) |
| PEG Fair Value | Relative | — | — | no | — |
| Earnings Yield | Earnings | — | — | no | — |
| Funds From Operations Multiple | Relative | — | — | no | — |
| Clinical Phase NPV | Growth | — | — | no | — |
| Merton | Asset | — | — | no | — |
| V5 Mechanical | — | — | — | no | — |
Solvency
| Field | Value |
|---|---|
| Net cash | $36.9m |
| Share count CAGR (dilution) | 1.6% |
| Burning cash | yes |
Operating profit is negative or near zero and the company has no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so years-to-repay cannot be computed honestly.
Operating profit is negative or near zero and there is no demonstrated through-cycle (mid-cycle) operating margin to normalize against, so interest coverage cannot be computed honestly.
Bullet Takeaways
Aehr Test Systems is a small semiconductor test and burn-in maker priced as a growth story, not as the business its current financials describe. At $115.51 the price reads against sales at roughly 73x revenue, the most demanding end of the scale, because the company is loss-making and burning cash on a trailing basis.
The story is the pivot away from silicon-carbide EV concentration toward AI processors, data-center burn-in, gallium nitride, and silicon photonics. Q3 fiscal 2026 bookings jumped to $37.2M from $6.2M the prior quarter, and management guides full-year fiscal 2026 revenue to the high side of $45M to $50M with a return to non-GAAP profitability targeted for the fourth quarter.
The balance sheet is clean: no debt and about $37M of liquid assets, which funds the company through the transition without dilution pressure today. The entire bet is whether the AI burn-in demand is durable enough to fill a small, lumpy order book that has historically swung hard with one end market.
Bull Case
Start with how Aehr is allocating its capital and balance sheet, because for a company at this stage that is the clearest signal of management's read on its own opportunity. Aehr runs with no debt and about $37M of cash, and it is deploying that capacity into capacity itself: a new contract-manufacturing partnership capable of producing 20 Sonoma systems per month, built to meet anticipated demand spikes in late 2026, and the earlier InCal acquisition that broadened the product line into package-part burn-in and opened new addressable markets. A company that is scaling manufacturing and integrating an acquisition rather than conserving cash is telling you it believes the order book is about to inflect. The numbers back the posture: Q3 fiscal 2026 bookings of $37.2M against just $6.2M the prior quarter, driven by purchase orders for FOX systems, WaferPaks, and Auto Aligners across AI, silicon photonics, and silicon carbide customers.
The second pillar is the size of the burn-in opportunity the AI build-out creates. Aehr's machines do wafer-level and package-level test and burn-in, and the filing describes the workflow precisely: "loading of the customer's modules to the DiePak Carrier so that the modules can be tested and burned-in by the FOX-XP and FOX-NP system" (FY2025 10-K, accession 0001654954-25-008553). Management estimates that only about 5% of ASICs and 50% of AI accelerators currently undergo production burn-in, which frames a large headroom if the industry moves toward burning in more high-value AI silicon to catch early-life failures before they reach a data center. For chips that cost tens of thousands of dollars and sit in systems that cannot tolerate field failures, the economic case for more burn-in is strong, and Aehr is one of the few specialists positioned for it.
The third pillar is the diversification away from the single-market dependence that hurt the stock. After two years where silicon carbide for electric vehicles dominated revenue, and where EV softness drove a sharp sales decline, Aehr is now winning engagements in AI processors, gallium nitride power semiconductors, data storage, silicon photonics, and flash memory. The InCal integration accelerated delivery volume and product breadth. If that broadening holds, the business becomes less hostage to any one end market's cycle, and the return to non-GAAP profitability management guides for the fiscal fourth quarter would be the first proof point that the new mix can carry fixed costs.
Bear Case
The bear case starts with the moat, because Aehr's defensible advantage is narrower than the AI narrative implies, and the data shows where it can erode. Aehr is a small, specialized equipment vendor whose historical strength was concentrated in silicon-carbide wafer-level burn-in. The risk is that the very diversification the bull case celebrates, into AI processors and gallium nitride and silicon photonics, puts Aehr into markets where larger automated-test-equipment companies already compete and where the customers are sophisticated chipmakers who can design around a single supplier or bring test in-house. Burn-in is valuable, but it is also a step many high-volume producers try to minimize, and the 5%-of-ASICs figure cuts both ways: it is upside if adoption rises, but it also means most of the industry has so far chosen not to burn in these parts. A moat that depends on the industry changing its standard practice is a thesis, not a position.
The second and sharper risk is customer concentration, which the filing names explicitly: "the concentration of our customer base increases risks related to the financial condition of our customers, and the deterioration in financial condition of a single customer or the failure of a single customer" can hurt results (FY2025 10-K, accession 0001654954-25-008553). When a handful of customers drive a large share of revenue, the order book is lumpy and binary. That is exactly what the numbers show: bookings swung from $6.2M to $37.2M in a single quarter. A book that lumpy can disappoint just as violently as it surprised, and a small company carrying high fixed costs against that volatility can swing back to losses on one delayed program. The trailing operating loss and cash burn are the current evidence of how unforgiving that operating leverage is on the downside.
The third problem is the valuation itself, which leaves no room for the transition to stumble. The price reads against sales at about 73x revenue and implies the business eventually reaches a roughly 16% operating margin while sustaining revenue growth beyond 25% per year for an implausibly long horizon. That is the most demanding end of the scale, and historically only about 30% of comparable fast-growers sustained such a pace for even five years. Every grounded valuation method, the margin-trajectory model near $0.55, the earnings-power value near $0.74, and the book-value-floored excess-return models near $4 to $4.50, sits a fraction of the $115.51 price (June 27, 2026). The stock is priced as if the AI burn-in market is already won. If bookings normalize back toward the lumpy historical pattern, the gap between price and any earnings-grounded value is enormous.
Valuation
Aehr is the clearest example in this group of a price that cannot be resolved as a normal valuation. Because trailing operating profit is negative, the price is read against sales, and at about 73x revenue the inversion does not produce a clean implied growth rate; it produces a bound. The price implies the business eventually earns roughly a 16% operating margin and sustains revenue growth beyond 25% per year for a horizon long enough that the engine flags the assumption as extreme and not resolvable as a revenue bet.
The grounded methods all land far below price, which is the honest signal here. Book value per share is about $4.52, so the excess-return models that floor at book come in near $4 to $4.50. The margin-trajectory model, which ramps margin from deeply negative toward 12%, lands near $0.55, and the earnings-power value, which capitalizes a near-zero normalized EBIT, lands near $0.74. The P/S and relative methods land near $3.69 on a sector multiple. None of these support a price anywhere near $115.51, because none of them can credit a future that has not yet shown up in revenue or margin.
The practical read is that this is not an asset-value or earnings-power purchase; it is a pure bet on the AI burn-in market materializing at scale and Aehr capturing it. The valuation offers no cushion. The case rests entirely on bookings durability and the path to the management-guided return to profitability, and any reader weighing the stock is underwriting that outcome at today's price, not buying a discount to a calculable value.
Catalysts
Aehr's most recent quarter, fiscal Q3 2026, was a swing higher on bookings, which reached $37.2M versus $6.2M the prior quarter, spanning AI, silicon photonics, and silicon carbide customers. Management guided full-year fiscal 2026 revenue to the high side of the $45M to $50M range and projected a return to non-GAAP profitability in the fiscal fourth quarter, which is the single most important near-term catalyst: the first quarter that proves the new revenue mix can cover the cost base.
The operational catalyst is capacity coming online. The new contract-manufacturing partnership built to produce 20 Sonoma systems per month is positioned for anticipated demand spikes in late 2026, so shipment volume and any further large purchase orders are the signals to watch for whether the AI burn-in demand is converting from engagements into revenue. Continued diversification wins in gallium nitride, silicon photonics, data storage, and flash memory would each reduce the single-market dependence that has driven past volatility.
The risk to the catalyst path is the same lumpiness that produced the upside: a small order book tied to a concentrated customer base can disappoint as sharply as it surprised, and EV-related silicon-carbide softness already showed how fast revenue can fall when one end market cools. The stock trades on the narrative of AI processor and data-center burn-in adoption, so the catalysts that matter most are concrete production-burn-in commitments from large AI chip customers rather than guidance alone.
Peer Cohorts (Per Segment, With Filing Citations)
Aehr Test Systems (single segment - semiconductor test & burn-in) (reported)
- COHU (COHU INC)
- FY2025 10-K: …solutions, and software analytics to optimize semiconductor manufacturing yield and productivity. We offer a comprehensive suite of equipment, interface solutions, software, spares and services designed to address the evolving requirements of global semiconductor manufacturers. Our products support customers across…
- FY2025 10-K: " in Part IV, Item 15(a) of this Form 10-K. Marketing Efforts Cohu markets its solutions globally through a direct sales organization and technical marketing managers focused on expanding our presence in high growth semiconductor segments. Our commercial model is primarily driven by a direct sales force supported by…
- TER (TERADYNE, INC.)
- FY2025 10-K: …systems manufactured internally over a six-year life to cost of revenues, engineering and development, and selling and administrative expenses. Teradyne often sells internally manufactured test equipment to customers. Upon the sale of an internally manufactured test system, the net book value of the system is…
- FY2025 10-K: …including consumer electronics, wireless, automotive, industrial, computing, communications, and aerospace and defense industries. Teradyne's robotics product offerings consist primarily of collaborative robotic arms and autonomous mobile robots used by global manufacturing, logistics and industrial customers to…
- FORM (FormFactor, Inc.)
- FY2025 10-K: …vacuum probing, cryogenic probing, high-pressure probing, photonics testing, and a variety of other specialized applications. We are collaborating with certain customers to transition from the lab to the fab with co-packaged optics, which is poised to revolutionize chip-to-chip communication in the data center by…
- FY2025 10-K: …from customers that have greater volume purchasing power. There has also been consolidation within the semiconductor test equipment market. This consolidation trend could change our interactions and relationships with complementary tester, instrument, and probe card suppliers, and negatively impact our revenue and…
Methodology Note
- Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
- Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
- Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
- Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.
Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.